Last updated on September 2006

A Dose Study of Doxil in a Dose Dense 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions: Diffuse Large B Cell Lymphoma | Lymphoma | Non-Hodgkin
• Age: Between 18 - 100 Years
• Gender: Male or Female

• Other:
  60 years old and older or 18 years old and older with significant/potential cardiac
  morbidity
  Diagnosis of diffuse large B cell lymphoma, Ann Arbor stage I-IV, any International
  Prognostic Index (IPI) score.
  Previously untreated
  New York Heart Association (NYHA) classification of Class III or better
  Baseline ejection fraction (EF) > 25%
  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3
  Unless attributable to NHL: absolute neutrophil count (ANC) > 1500/uL, platelets >
  100,000/uL; hemoglobin > 9.0 g/dl
  Bilirubin < 1.5 mg/dL (unless related to lymphoma)
  Hepatic: transaminases < 2.5 x upper limit of normal (ULN) (unless related to
  lymphoma)
  Creatinine < 2.5 mg/dl (unless related to lymphoma)
  

You may not be eligible for this study if the following are true:

• No HIV+ individuals
  No primary central nervous system (CNS) lymphoma
  No pregnant or lactating women
  No serious active infection
  History of prior malignancy within the last 5 years other than subject's original
  cancer diagnosis listed in inclusion criteria with the exception of curatively
  treated basal cell carcinoma.